КРАХ Дэвид Л. (US),ДЕХАВЕН Джилл (US),КРИСС Дженнифер А. (US),БАРР Коллин М. (US),ЯГОДИЧ Мэри (US)
申请号：
RU2013109417/15
公开号：
RU2013109417A
申请日:
2011.08.04
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. Inactivated chickenpox virus (VZV), where VZV infectivity is undetectable, and where, when administered to a patient, inactivated VZV elicits an immune response against VZV. 2. A pharmaceutical composition comprising a therapeutically effective amount of VZV according to claim 1 and a pharmaceutically acceptable carrier. The pharmaceutical composition according to claim 2, wherein the infectivity of the inactivated VZV is ≤0.040 plaque forming units (PFU) / ml. The pharmaceutical composition according to claim 3, wherein the infectivity of the inactivated VZV is ≤0.010 plaque forming units (PFU) / ml. The pharmaceutical composition according to claim 4, wherein the infectivity of the inactivated VZV is ≤0.002 plaque forming units (PFU) / ml. 6. The pharmaceutical composition according to any one of claims 2 to 5, wherein the VZV strain is an Oka strain or a derivative of an Oka strain. 7. The pharmaceutical composition of claim 6, wherein the composition is lyophilized. The pharmaceutical composition of claim 7, wherein the VZV is inactivated by gamma radiation. The pharmaceutical composition of claim 8, wherein the immune response elicited by the composition is not substantially different from the immune response elicited by a control sample containing a similar amount of uninactivated VZV.10. The pharmaceutical composition of claim 9, wherein the immune response elicited by an inactivated VZV differs from the immune response elicited by a control sample by 25% or less. The pharmaceutical composition according to any one of claims 2 to 5, wherein VZV infectivity is determined by analysis of the formation of chickenpox plaques. A method of producing inactivated chickenpox virus (VZV), comprising gamma irradiation of a sample containing VZV, using from about 5 to about1. Инактивированный вирус ветряной оспы (VZV), где инфекционность VZV является необнаруживаемой, и где при введении пациенту инактивированный VZV вызывает иммунный ответ против VZV.2. Фармацевтическа
